Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 5;8(1):181.
doi: 10.1038/s41398-018-0191-x.

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function

Affiliations
Randomized Controlled Trial

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function

Celia J A Morgan et al. Transl Psychiatry. .

Abstract

The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8 mg, (iii) CBD 16 mg and (iv) THC 8 mg + CBD 16 mg administered by inhalation through a vaporiser. Using an experimental medicine approach to predict treatment sensitivity, we selected 48 cannabis users from the community on the basis of (1) schizotypal personality questionnaire scores (low, high) and (2) frequency of cannabis use (light, heavy). The Brief Psychiatric Rating Scale (BPRS), Psychotomimetic States Inventory (PSI), immediate and delayed prose recall (episodic memory), 1- and 2-back (working memory) were assessed on each day. Results indicated that THC increased overall scores on the PSI, negative symptoms on BPRS, and robustly impaired episodic and working memory. Co-administration of CBD did not attenuate these effects. CBD alone reduced PSI scores in light users only. At a ratio of 2:1, CBD does not attenuate the acute psychotic and memory impairing effects of vaporised THC. Frequent cannabis users may show a blunted anti- psychotic response to CBD, which is of concern due to the high rates of cannabis use disorders in patients with schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Effects of THC and CBD alone and in combination, along with placebo, across the whole sample on subscales of psychotomimetic symptoms (PSI). THC and THC + CBD increased perceptual distortions (b) and cognitive disorganisation (c) but not other subscales (a; d; e; f). THC = T (Black shading), THC + CBD = T (grey shading), CBD = C, Placebo = P
Fig. 2
Fig. 2
Analysis of effects of THC, CBD, the combination and placebo in low frequency (light) and high frequency (heavy) cannabis users on total psychotomimetic symptom scores
Fig. 3
Fig. 3
Effects of THC, CBD, the combination and placebo on positive and negative symptoms on the Brief Psychiatric Rating Scale
Fig. 4
Fig. 4
Effects of THC, CBD, the combination and placebo on episodic memory on the prose recall task
Fig. 5
Fig. 5
Working memory. Effects of THC, CBD, the combination and placebo on working memory in the N back task, for a d′ an index of discriminability, and b reaction time on the task

Comment in

Similar articles

Cited by

References

    1. UNODC. United Nations Office on Drugs and Crime. World Drug Report 2016.
    1. Curran HV, et al. Keep off the grass? Cannabis, cognition and addiction. Nat. Rev. Neurosci. 2016;17:293–306. doi: 10.1038/nrn.2016.28. - DOI - PubMed
    1. van Winkel R. Family-based analysis of genetic variation underlying psychosis- inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry. 2011;68:148–157. doi: 10.1001/archgenpsychiatry.2010.152. - DOI - PubMed
    1. Di Forti M, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol. Psychiatry. 2012;72:811–816. doi: 10.1016/j.biopsych.2012.06.020. - DOI - PubMed
    1. Morgan C, Freeman T, Powell J, Curran H. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl. Psychiatry. 2016;6:e738. doi: 10.1038/tp.2015.219. - DOI - PMC - PubMed

Publication types